Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial
Journal of Clinical Oncology · 2024
DOI: 10.1200/jco.23.01687 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Vincent Camus und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Centre Henri Becquerel, Rouen, France. Hauptthemen laut MEDLINE: Lymphoma, T-Cell, Peripheral, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Doxorubicin. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The primary analysis of the Ro-CHOP phase III randomized controlled trial (ClinicalTrials.gov identifier: NCT01796002 ) established that romidepsin (Ro) plus cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) did not yield an increased efficacy compared with CHOP alone as first-line treatment of peripheral T-cell lymphoma. We report the planned final analysis 5 years after the last patient enrolled. With a median follow-up of 6 years, median progression-free survival (PFS) was 12.0 months compared with 10.2 months (hazard ratio [HR], 0.79 [95% CI, 0.62 to 1.005]; P = .054), while median overall survival was 62.2 months (35.7-86.6 months) and 43.8 months (30.1-70.2 months; HR, 0.88 [95% CI, 0.68 to 1.14]; P = .324) in the Ro-CHOP and CHOP arms, respectively. In an exploratory analysis, the median PFS in the centrally reviewed follicular helper T-cell lymphoma subgroup was significantly longer in the Ro-CHOP arm (19.5 v 10.6 months, HR, 0.703 [95% CI, 0.502 to 0.985]; P = .039). Second-line treatments were given to 251 patients with a median PFS2 and OS2 after relapse or progression of 3.3 months and 11.5 months, respectively. Within the limits of highly heterogeneous second-line treatments, no specific regimen seemed to provide superior disease control. However, a potential benefit was observed with brentuximab vedotin in association with chemotherapy even after excluding anaplastic large-cell lymphoma subtype or after adjusting for histology and international prognostic index in a multivariate model (HR for PFS, 0.431 [95% CI, 0.238 to 0.779]; P = .005).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Centre Henri Becquerel, Rouen, France.
- Hematology Department, Hospital Saint-Louis, Paris, France.
- Department of Pathology and InsermU955, University Hospital Henri Mondor, Créteil, France.
- Service d'Hematologie adultes, Hopital Universitaire Necker Enfants Malades, AP-HP, Paris, France.
- Department of Hematology, CHU Dijon-Bourgogne and INSERM 1231, Dijon, France.
- IUCT Oncopole, Toulouse, France.
ORCID-Profile: Vincent Camus, Catherine Thieblemont, Philippe Gaulard, Rene-Olivier Casasnovas, Loïc Ysebaert, Gandhi Laurent Damaj, Won Seog Kim, Soon Thye Lim, Marc Andre, Norma Gutiérrez, Maria Jesus Penarrubia, Philipp B Staber, Judith Trotman, Andreas Hüttmann, Alessandra Tucci, Patrick Fogarty, Marie-Helene Delfau-Larue, Emmanuel Itti, Laurence de Leval, Franck Morschhauser, Emmanuel Bachy
Zitieren
APA
Camus, V., Thieblemont, C., Gaulard, P., Cheminant, M., Casasnovas, R. O., Ysebaert, L., Damaj, G. L., Guidez, S., Pica, G. M., Kim, W. S., Lim, S. T., Andre, M., Gutiérrez, N., Penarrubia, M. J., Staber, P. B., Trotman, J., Hüttmann, A., Stefoni, V., Tucci, A., …, & Bachy, E. (2024). Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01687
Vancouver
Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01687
BibTeX
@article{Camus2024,
author = {Camus, Vincent and Thieblemont, Catherine and Gaulard, Philippe and Cheminant, Morgane and Casasnovas, Rene-Olivier and Ysebaert, Loïc and Damaj, Gandhi Laurent and Guidez, Stéphanie and Pica, Gian Matteo and Kim, Won Seog and Lim, Soon Thye and Andre, Marc and Gutiérrez, Norma and Penarrubia, Maria Jesus and Staber, Philipp B and Trotman, Judith and Hüttmann, Andreas and Stefoni, Vittorio and Tucci, Alessandra and Fogarty, Patrick and Farhat, Hassan and Abraham, Julie and Abarah, Wajed and Belmecheri, Fatiha and Ribrag, Vincent and Delfau-Larue, Marie-Helene and Cottereau, Anne-Ségolène and Itti, Emmanuel and Li, Ju and Delarue, Richard and de Leval, Laurence and Morschhauser, Franck and Bachy, Emmanuel},
title = {Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
doi = {10.1200/jco.23.01687}
}
EUVIMED